Kumar Vikas, Guru Santosh K, Jain Shreyans K, Joshi Prashant, Gandhi Sumit G, Bharate Sandip B, Bhushan Shashi, Bharate Sonali S, Vishwakarma Ram A
Preformulation Laboratory, CSIR-Indian Institute of Integrative Medicine, Canal Road, Jammu 180001, India; Academy of Scientific & Innovative Research (AcSIR), CSIR-Indian Institute of Integrative Medicine, Canal Road, Jammu 180001, India.
Cancer Pharmacology Division, CSIR-Indian Institute of Integrative Medicine, Canal Road, Jammu 180001, India.
Bioorg Med Chem Lett. 2016 Aug 1;26(15):3457-63. doi: 10.1016/j.bmcl.2016.06.046. Epub 2016 Jun 16.
Rohitukine is a chromone alkaloid isolated from an Indian medicinal plant Dysoxylum binectariferum. This natural product has led to the discovery of two clinical candidates (flavopiridol and P276-00) for the treatment of cancer. Herein, for the first time we report an efficient protocol for isolation and purification of this precious natural product in a bulk-quantity from leaves (a renewable source) of D. binectariferum (>98% purity) without use of chromatography or any acid-base treatment. Despite of the fact that this scaffold has reached up to clinical stage, particularly for leukemia; however the antileukemic activity of a parent natural product has never been investigated. Furthermore, rohitukine has never been studied for cyclin-dependent kinase (Cdk) inhibition, kinase profiling and for its experimental physicochemical properties. Thus, herein, we report in vitro cytotoxicity of rohitukine in a panel of 20 cancer cell lines (including leukemia, pancreatic, prostate, breast and CNS) and 2 normal cell lines; kinase profiling, Cdk2/9 inhibition, and physicochemical properties (solubility and stability in biological medias, pKa, LogP, LogD). In cytotoxicity screening, rohitukine displayed promising activity in HL-60 and Molt-4 (leukemia) cell lines with GI50 of 10 and 12μM, respectively. It showed inhibition of Cdk2/A and Cdk9/T1 with IC50 values of 7.3 and 0.3μM, respectively. The key interactions of rohitukine with Cdk9 was also studied by molecular modeling. Rohitukine was found to be highly water soluble (Swater=10.3mg/mL) and its LogP value was -0.55. The ionization constant of rohitukine was found to be 5.83. Rohitukine was stable in various biological media's including rat plasma. The data presented herein will help in designing better anticancer agents in future.
罗希图碱是一种从印度药用植物双腺蒲桃中分离出的色酮生物碱。这种天然产物促使人们发现了两种用于治疗癌症的临床候选药物(黄酮哌啶醇和P276 - 00)。在此,我们首次报道了一种高效的方法,可从双腺蒲桃的叶子(一种可再生资源)中大量分离和纯化这种珍贵的天然产物(纯度>98%),且无需使用色谱法或任何酸碱处理。尽管这种药物支架已进入临床阶段,尤其是针对白血病;然而,从未对母体天然产物的抗白血病活性进行过研究。此外,从未对罗希图碱的细胞周期蛋白依赖性激酶(Cdk)抑制作用、激酶谱分析及其实验物理化学性质进行过研究。因此,在此我们报道了罗希图碱在一组20种癌细胞系(包括白血病、胰腺、前列腺、乳腺和中枢神经系统癌细胞系)和2种正常细胞系中的体外细胞毒性;激酶谱分析、Cdk2/9抑制作用以及物理化学性质(在生物介质中的溶解度和稳定性、pKa、LogP、LogD)。在细胞毒性筛选中,罗希图碱在HL - 60和Molt - 4(白血病)细胞系中显示出有前景的活性,其GI50分别为10和12μM。它分别以7.3和0.3μM的IC50值显示出对Cdk2/A和Cdk9/T1的抑制作用。还通过分子建模研究了罗希图碱与Cdk9的关键相互作用。发现罗希图碱具有高度水溶性(S水 = 10.3mg/mL),其LogP值为 - 0.55。罗希图碱的电离常数为5.83。罗希图碱在包括大鼠血浆在内的各种生物介质中均稳定。本文提供的数据将有助于未来设计出更好的抗癌药物。